Related references
Note: Only part of the references are listed.Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
B. Porte et al.
BREAST (2020)
Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy
Leticia Varella et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Breast cancer statistics, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy
Maria Teresa Masucci et al.
FRONTIERS IN ONCOLOGY (2019)
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
Jessica L. F. Teh et al.
CLINICAL CANCER RESEARCH (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3
Massimo Cristofanilli et al.
EUROPEAN JOURNAL OF CANCER (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval
J. K. Kish et al.
BREAST CANCER RESEARCH (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients
Mirco Pistelli et al.
BMC CANCER (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Seth B. Coffelt et al.
NATURE (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
How neutrophils shape adaptive immune responses
Pieter H. C. Leliefeld et al.
FRONTIERS IN IMMUNOLOGY (2015)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting
Young Wha Koh et al.
TUMOR BIOLOGY (2014)
New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation
Andrew D. Wells et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences
Janesh Pillay et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2013)
Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients
Hany Noh et al.
JOURNAL OF BREAST CANCER (2013)
Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients
Basem Azab et al.
MEDICAL ONCOLOGY (2013)
Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients
Basem Azab et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology
Claudia A. Dumitru et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
G. K. Schwartz et al.
BRITISH JOURNAL OF CANCER (2011)
Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model
Jadwiga Jablonska et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Neutrophils: key mediators of tumour angiogenesis
Simon Tazzyman et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis
Veronica C. Ardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study
Manfred Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17
PE Goss et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Share Paper
